Perennial Allergic Rhinitis Clinical Trial
Official title:
Randomized Clinical Study for Efficacy Assessment Between Cloratadd-D, Loratadine + Pseudoephedrine (Coated Pill), Produced by EMS S/A Laboratories and Allegra-D , Produced by Sanofi-Aventis for Patients With Perennial Allergic Rhinitis.
The loratadine-pseudoephedrine combination has proven to be more effective than the use of these individual components. This prospective, randomized, double-blind and paralel study, in which patients with perennial allergic rhinitis receive one of loratadine + pseudoephedrine association drug for treatment of signs and symptoms during 4 weeks.
The effectiveness of treatment in each drug group will be evaluate by global improvement of signs (nasal mucous edema, ocular hyperemia, nasal secretion) and symptoms (itching eye, tearing,itching nose, itching on the palate) of perennial allergic rhinitis, after 4 weeks of treatment. Symptoms as rhinorrhea, nasal congestion, itching nose, sneezing and itching eye were considered as secondary efficacy endpoint, along with the questionnaire of quality of life SF-36. Safety evaluation data will include report of all adverse events (including type, frequency, instensity, seriousness, severity and action taken related to investigational product) reported by patients, parents or legal responsible, ou observed by Investigator. ;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01654536 -
A 6 Month Safety Study Of Ciclesonide Nasal Aerosol (Zetonna®) And Ciclesonide Nasal Spray (Omnaris®) In Subjects 12 Years And Older With Perennial Allergic Rhinitis (PAR)
|
Phase 4 | |
| Completed |
NCT01539304 -
Clinical Trial to Evaluate the Safety and Efficacy of "CITUS Dry Syrup" in Children With Perennial Allergic Rhinitis
|
Phase 3 | |
| Completed |
NCT01221285 -
Development of Cockroach Immunotherapy by the Inner-City Asthma Consortium
|
Phase 1 | |
| Terminated |
NCT00491374 -
Study of Nasonex® in Improving Sleep Disturbances Related to Perennial Allergic Rhinitis (Study P04909)(TERMINATED)
|
Phase 4 | |
| Completed |
NCT00783224 -
A Comparative Study of Mometasone Furoate Nasal Spray and Fluticasone Propionate Nasal Spray in Patients With Perennial Allergic Rhinitis (Study P04512)
|
Phase 3 | |
| Completed |
NCT04324918 -
Efficacy and Safety of HCP1102 Capsule in Patients With Perennial Allergic Rhinitis
|
Phase 3 | |
| Completed |
NCT02532179 -
Subcutaneous Immunotherapy for Mouse in Adults
|
Phase 1/Phase 2 | |
| Completed |
NCT01451541 -
A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Perennial Allergic Rhinitis (PAR).
|
Phase 3 | |
| Enrolling by invitation |
NCT01062139 -
Cosalin® Monotherapy Versus Cosalin® and Xarlin® Combination Therapy
|
Phase 4 | |
| Completed |
NCT00405899 -
Pilot Study of Allergy Immunotherapy and Prevention of Viral Respiratory Infections
|
N/A | |
| Completed |
NCT01549340 -
Retrospective Record Review of Adults and Children Advised for Allergen Immunotherapy (MK-7243-022)
|
N/A | |
| Completed |
NCT01018862 -
A Study to Evaluate the Safety and Efficacy of a Nasal Spray to Treat Children With Perennial Allergic Rhinitis
|
Phase 3 | |
| Completed |
NCT00789555 -
Safety of PATANASE Nasal Spray in Patients With Perennial Allergic Rhinitis
|
Phase 4 | |
| Completed |
NCT00261287 -
Safety and Tolerability of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis (2-5 Years Old) (BY9010/M1-416)
|
Phase 3 | |
| Completed |
NCT00974571 -
Montelukast in Perennial Allergic Rhinitis - 2001-2002 Study (0476-246)
|
Phase 3 | |
| Completed |
NCT04654702 -
Observational Study to Evaluate Therapeutic Effectiveness and Safety of Monterizine Cap.
|
||
| Completed |
NCT05122143 -
Efficacy and Safety of AM-301 on Allergic Symptoms of Perennial Allergic Rhinitis Sufferers
|
N/A | |
| Completed |
NCT01380327 -
Biomarkers of Cockroach Sublingual Immunotherapy 2
|
Phase 1/Phase 2 | |
| Completed |
NCT01116778 -
the Efficacy and Safety of Probiotics eN-Lac® Capsules of Children With Perennial Allergic Rhinitis
|
Phase 3 | |
| Completed |
NCT00359216 -
The Effects of Mometasone Furoate Nasal Spray in Subjects With Sleep-disordered Breathing (SDB) Associated With Perennial Allergic Rhinitis (Study P04726)
|
Phase 4 |